A Phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme

Morris D. Groves, Moshe H. Maor, Christina Meyers, Athanassios P. Kyritsis, Kurt A. Jaeckle, W. K.Alfred Yung, Raymond E. Sawaya, Kenneth Hess, Janet M. Bruner, Pamela Peterson, Victor A. Levin

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

Purpose: To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme. Methods and Materials: Between 1994 and 1996, 88 patients were enrolled to receive 1,9 Gy of radiation three times a day for two 5-day cycles separated by 2 weeks; each 5-day cycle was preceded by a continuous 96-hour infusion of BrdU at a dose of 2.1 g/m2/day. After radiotherapy, patients received PCV chemotherapy. Results: Median survival for all 88 patients was 50 weeks, seventy (79.5%) received one or more courses of PCV; their median survival was 57 weeks. Covariates predictive of improved survival were gross total versus subtotal resection or biopsy (p = 0.0048) and radiation dose ≥ 56 Gy (p = 0.019). While receiving BrdU, 47 patients (53%) suffered grade 3 or 4 thrombocytopenia or leukopenia; 22 patients (25%) suffered grade 3 or 4 dermatologic toxicity. Conclusion: Survival was not extended in patients with glioblastoma or gliosarcoma who received BrdU at the dose and administration schedule used in this study. The BrdU dose used in this study resulted in substantial myelosuppressive and dermatologic toxicity.

Original languageEnglish (US)
Pages (from-to)127-135
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume45
Issue number1
DOIs
StatePublished - Aug 1 1999

    Fingerprint

Keywords

  • Accelerated fractionated radiotherapy
  • Bromodeoxyuridine (BrdU)
  • Glioblastoma

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Groves, M. D., Maor, M. H., Meyers, C., Kyritsis, A. P., Jaeckle, K. A., Yung, W. K. A., Sawaya, R. E., Hess, K., Bruner, J. M., Peterson, P., & Levin, V. A. (1999). A Phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. International Journal of Radiation Oncology Biology Physics, 45(1), 127-135. https://doi.org/10.1016/S0360-3016(99)00122-4